Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | FNTA | P49354 | 5/20 | 0.46 |
| ▸ | FNTB | P49356 | 5/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672213 | 1.00 | ACHE (0.55) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7190137 | 1.00 | ACHE (0.55) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7674838 | 0.90 | ACHE (0.49) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7671225 | 0.89 | ACHE (0.48) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL11303517 | 0.88 | ACHE (0.48) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7672251 | 0.86 | ACHE (0.46) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7672935 | 0.86 | ACHE (0.52) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7679631 | 0.86 | OPRM1 (0.46) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7676804 | 0.86 | ACHE (0.51) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| SCHEMBL7679182 | 0.85 | ACHE (0.51) | ACHESLC22A1CHRM2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002079147-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | ACHE 4845/4885SLC22A1 3199/4885CHRM2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.